A clinicopathological score has been proposed by Trouillas et al. to predict the evolution of pituitary adenomas. Aim of our study was to perform an independent external validation of this score and identify other potential predictor of post-surgical outcome.
The study sample included 566 patients with pituitary adenomas, specifically 253 FSH/LH-secreting, 147 GH-secreting, 85 PRL-secreting, 72 ACTH-secreting and 9 TSH-secreting tumours with at least 3-year post-surgical follow-up.
In 437 cases, pituitary adenomas were non-invasive, with low (grade 1a: 378 cases) or high (grade 1b: 59 cases) proliferative activity. In 129 cases, tumours were invasive, with low (grade 2a: 87 cases) or high (grade 2b: 42 cases) proliferative activity. During the follow-up (mean: 5.8 years), 60 patients developed disease recurrence or progression, with a total of 130 patients with pituitary disease at last follow-up. Univariate analysis demonstrated a significantly higher risk of disease persistence and recurrence/progression in patients with PRL-, ACTH- and FSH/LH-secreting tumours as compared to those with somatotroph tumours, and in those with high proliferative activity (grade 1b and 2b) or >1 cm diameter. Multivariate analysis confirmed tumour type and grade to be independent predictors of disease-free-survival. Tumour invasion, Ki-67 and tumour type were the only independent prognostic factors of disease-free survival.
Our data confirmed the validity of Trouillas’ score, being tumour type and grade independent predictors of disease evolution. Therefore, we recommend to always consider both features, together with tumour histological subtype, in the clinical setting to early identify patients at higher risk of recurrence.
OsamuraRYGrossmanAKorbonitsMKovacsKLopesMBSMatsunoATrouillasJ.Pituitary adenoma. In World Health Organization Classification of Tumours of Endocrine Organs4th ed. pp 14–18. Eds LloydRVOsamuraRYKloppelG & RosaiJ. Lyon: IARC2017.
RaverotGDantonyEBeauvyJVasiljevicAMikolasekSBorson-ChazotFJouanneauERoyPTrouillasJ.Risk of recurrence in pituitary neuroendocrine tumors: a prospective study using a five-tiered classification. Journal of Clinical Endocrinology and Metabolism20171023368–3374. (https://doi.org/10.1210/jc.2017-00773)
AsaSLCasar-BorotaOChansonPDelgrangeEEarlsPEzzatSGrossmanAIkedaHInoshitaNKaravitakiNet al. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocrine-Related Cancer201724C5–C8. (https://doi.org/10.1530/ERC-17-0004)
SaegerWLudeckeDKBuchfelderMFahlbuschRQuabbeHJPetersennS.Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. European Journal of Endocrinology2007156203–216. (https://doi.org/10.1530/eje.1.02326)
TrouillasJRoyPSturmNDantonyECortet-RudelliCViennetGBonnevilleJFAssakerRAugerCBrueTet al. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathologica2013126123–135. (https://doi.org/10.1007/s00401-013-1084-y)
ScheithauerBWGaffeyTALloydRVSeboTJKovacsKTHorvathEYapicierOYoungWFJrMeyerFBKurokiTet al. Pathobiology of pituitary adenomas and carcinomas. Neurosurgery200659341–353. (https://doi.org/10.1227/01.NEU.0000223437.51435.6E)
LloydRVKovacsKYoungWFJr. Tumors of the pituitary. In World Health Organization Classification of Tumors: Pathology and Genetics: Tumors of Endocrine Organs3th ed. pp 10–47. Eds DeLellisRALloydRVHeitzPU & EngC. Lyon: IARC2004.
RighiAAgatiPSistoAFrankGFaustini-FustiniMAgatiRMazzatentaDFarnediAMenettiFMarucciGet al. A classification tree approach for pituitary adenomas. Human Pathology2012431627–1637. (https://doi.org/10.1016/j.humpath.2011.12.003)
MarucciGFaustini-FustiniMRighiAPasquiniEFrankGAgatiRFoschiniMP.Thyrotropin-secreting pituitary tumours: significance of ‘atypical adenomas’ in a series of 10 patients and association with Hashimoto thyroiditis as a cause of delay in diagnosis. Journal of Clinical Pathology200962455–459. (https://doi.org/10.1136/jcp.2008.061523)
RighiAMorandiLLeonardiEFarnediAMarucciGSistoAFrankGFaustini-FustiniMZoliMMazzatentaDet al. Galectin-3 expression in pituitary adenomas as a marker of aggressive behavior. Human Pathology2013442400–2409. (https://doi.org/10.1016/j.humpath.2013.05.020)
RighiAFaustini-FustiniMMorandiLMontiVAsioliSMazzatentaDBacciAFoschiniMP.The changing faces of corticotroph cell adenomas: the role of prohormone convertase 1/3. Endocrine201756286–297. (https://doi.org/10.1007/s12020-016-1028-0)
RaverotGVasiljevicAJouanneauETrouillasJ.A prognostic clinicopathologic classification of pituitary endocrine tumors. Endocrinology and Metabolism Clinics of North America20154411–18. (https://doi.org/10.1016/j.ecl.2014.10.001)
MiermeisterCPPetersennSBuchfelderMFahlbuschRLüdeckeDKHölskenABergmannMKnappeHUHansVHFlitschJet al. Histological criteria for atypical pituitary adenomas – data from the German pituitary adenoma registry suggests modifications. Acta Neuropathologica Communications20151950. (https://doi.org/10.1186/s40478-015-0229-8)
GejmanRSwearingenBHedley-WhyteET. Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Human Pathology200839758–766. (https://doi.org/10.1016/j.humpath.2007.10.004)
ChiloiroSBianchiADogliettoFde WaureCGiampietroAFuscoAIacovazzoDTartaglioneLDi NardoFSignorelliFet al. Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review. Pituitary201417267–276. (https://doi.org/10.1007/s11102-013-0500-6)
WierinckxAAugerCDevauchellePReynaudAChevallierPJanMPerrinGFevre-MontangeMReyCFigarella-BrangerDet al. A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. Endocrine-Related Cancer200714887–900. (https://doi.org/10.1677/ERC-07-0062)
Del Basso De CaroMSolariDPagliucaFVillaAGuadagnoECavalloLMColaoAPettinatoGCappabiancaP.Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients. Neurosurgical Review201740105–114. (https://doi.org/10.1007/s10143-016-0740-9)
LelotteJMourinAFomekongEMichotteARaftopoulosCMaiterD.Both invasiveness and proliferation criteria predict recurrence of non-functioning pituitary macroadenomas after surgery: a retrospective analysis of a monocentric cohort of 120 patients. European Journal of Endocrinology2018178237–246. (https://doi.org/10.1530/EJE-17-0965)
MickoASWöhrerAWolfsbergerSKnospE.Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification. Journal of Neurosurgery2015122803–811. (https://doi.org/10.3171/2014.12.JNS141083)
NagataYInoshitaNFukuharaNYamaguchi-OkadaMNishiokaHIwataTYoshimotoKYamadaS.Growth hormone-producing pituitary adenomas in childhood and young adulthood: clinical features and outcomes. Pituitary2018211–9. (https://doi.org/10.1007/s11102-017-0836-4)